Umoja Biopharma
WA - SeattlePharmaceutical
Focus: Umoja Biopharma is a Seattle-based cellular immunotherapy platform company focused on oncology, operating at the Series C+ stage with a specialized focus on CAR-T and related cell therapy modalities.
Profile data last refreshed 12h ago · AI intelligence enriched 3w ago
Funding Stage
SERIES C +
Open Jobs
9+8 this month
Growing — net +8 jobs in 30d
18 jobs added vs 10 removed. Steady team buildout.
Should You Work at Umoja Biopharma?
AI assessmentStrong fit for scientists and clinical development professionals seeking high-impact platform work with leading CAR-T pioneers, but suitable only for candidates comfortable with extended pre-revenue risk and binary outcomes.
Why Work Here
- Join a cutting-edge cellular immunotherapy platform at a critical inflection point (Series C+) with board appointments of leading CAR-T experts (Dr. Marcela Maus, Dr. Athena Countouriotis) signaling strong scientific credibility.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
SCRI-E2CAR_EGFRtv1
OsteosarcomaClinical Trials (1)
NCT05312411A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma
Phase 1Help build intelligence for Umoja Biopharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.